Early this year, a dear friend—my classmate from kindergarten through high school, now a busy law firm owner—sent a message that still burns in my memory: “The cancer has metastasized.” Her decline was rapid. Soon after diagnosis, a fist-sized tumor gripped her abdomen, with cancer cells invading organs and necrotizing bones. By the time she texted, she lay bedridden, nearly mute, her body surrendering to stillness. Last week came a call that brought tears to my eyes. Her voice burst through the phone—clear, strong, alive. Over recent months, she has undergone an experimental immunotherapy at a Guangzhou clinic, a cutting-edge treatment pioneered by Chinese scientists yet to hit the market. Combined with other therapies, her tumor had shrunk to a grain of rice. Organs regained function, bones began regenerating, and she reclaimed mobility. “I’m taking cases again—got a team of lawyers to feed,” she said, half-joking, half-defiant. That day, she posted a photo online: four dishes she’d cooked for her family, a quiet triumph of normalcy. Her story is rare but radiant. The personalized therapy, though costly, worked miraculously. Initially misdiagnosed with pancreatic cancer, she’s now undergoing genetic testing to pinpoint her tumor’s origin. She may live with cancer indefinitely, facing risks like drug resistance, yet her spirit blazes. “When I asked my doctor for a timeline, he told me to stop counting,” she said. “With AI and new tech, treatments evolve faster than mutations. Just outpace the cells.” I share her conviction. Across China, life sciences are exploding with the urgency of high-speed rails and 5G networks—researchers sprinting to decode diseases, save lives. It’s tragic if such strides are branded “China threats”, met with sanctions. Yet life is full of surprises: perhaps someday, those pushing U.S.-China medical decoupling will themselves seek healing in new drugs from China. #The Cancer Care Collective #Science is awesome 🧬🦾🚀🤯 #Biohackers Connect https://www.scmp.com/news..